Lead Product(s): Clevegen
Therapeutic Area: Oncology
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Business Finland
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Funding May 11, 2020
Grant will enable characterization of immunological responses in MATINS trial. Clevegen to be studied in experimental combinations with anti-cancer molecules from other consortium members.